Table 3.

Change in quality metrics of stage 3 chronic kidney disease registry based on diabetes status prior to and after implementation of automated urinary albumin testing^a

Metric	April 2018	April 2019	April 2020	p value
Albuminuria testing within 1 y, %
Diabetes	38.1	81.7	77.8	< 0.001
No diabetes	20	83.9	75.2	< 0.001
ACE inhibitor or ARB use, %
Diabetes	78.8	78.7	78.3	0.83
No diabetes	57.6	57.9	59.5	0.07
ACE inhibitor or ARB use with renal indications,b %
Diabetes	78.5	81.3	80.8	0.18
No diabetes	73	76	78.4	0.39

^a Automated urinary albumin testing was implemented May 2018.

^b Renal indication for ACE inhibitor or ARB defined as active diagnosis of hypertension and random urinary albumin creatinine ratio > 30 mg/g in diabetics or random urinary albumin creatinine ratio > 300 mg/g in nondiabetics.

ACE = angiotensin-converting enzyme; ARB, angiotensin receptor blocker.